We are live on ! Find out more
FTH icon

Faeth Therapeutics

19 hedge funds and large institutions have $1.32M invested in Faeth Therapeutics in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

119% more capital inflows, than outflows

Capital inflows: $112K | Capital outflows: $51K

0.37% more ownership

Funds ownership: 8.4% → 8.77% (+0.37%)

17% less funds holding

Funds holding: 23 → 19 (-4)

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

Holders
19
Holders Change
-4
Holders Change %
-17.39%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
4
Reduced
5
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

FTH Hedge Fund Activity: Q3 2024 in Review

19 of the 6,987 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q3 2024, worth a combined $1.32M — up 1% from $1.31M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of FTH and 1 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 4 added.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $55.2K. The largest seller was Bridgeway Capital Management, cutting an estimated $18.3K.

  • 19 institutional investors held Faeth Therapeutics (FTH) as of Q3 2024, down from 23 in Q2 2024.
  • Funds reported $1.32M of Faeth Therapeutics stock for Q3 2024, up 1% quarter-over-quarter.
  • 1 fund opened new Faeth Therapeutics positions in Q3 2024 and 5 closed out, a net change of -4 holders.
  • The largest Faeth Therapeutics buyer in Q3 2024 was Susquehanna International Group, an estimated $55.2K added.
  • The largest Faeth Therapeutics seller in Q3 2024 was Bridgeway Capital Management, an estimated $18.3K sold.

Based on aggregated 13F filings for Q3 2024.